These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18393794)

  • 1. Production and fate of amyloid peptides: recent advances and perspectives.
    Checler F
    Curr Alzheimer Res; 2008 Apr; 5(2):90-1. PubMed ID: 18393794
    [No Abstract]   [Full Text] [Related]  

  • 2. Unraveling the tangled brain of Alzheimer's.
    Wolfson W
    Chem Biol; 2008 Feb; 15(2):89-90. PubMed ID: 18291309
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting nascent soluble Aβ42 for potential Alzheimer drug development.
    Zhang M; Hausmann L; Song W
    J Neurochem; 2013 May; 125(3):329-31. PubMed ID: 23405973
    [No Abstract]   [Full Text] [Related]  

  • 4. Alzheimer's disease drug development based on Computer-Aided Drug Design.
    Zeng H; Wu X
    Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting amyloid precursor protein.
    Hermey G
    Ann Neurol; 2011 Jan; 69(1):8-10. PubMed ID: 21280070
    [No Abstract]   [Full Text] [Related]  

  • 6. Progress toward the discovery and development of efficacious BACE inhibitors.
    Durham TB; Shepherd TA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.
    Crunkhorn S
    Nat Rev Drug Discov; 2016 Dec; 16(1):18. PubMed ID: 28031572
    [No Abstract]   [Full Text] [Related]  

  • 8. Monitoring β-secretase activity in living cells with a membrane-anchored FRET probe.
    Folk DS; Torosian JC; Hwang S; McCafferty DG; Franz KJ
    Angew Chem Int Ed Engl; 2012 Oct; 51(43):10795-9. PubMed ID: 23023944
    [No Abstract]   [Full Text] [Related]  

  • 9. Partial loss of CALM function reduces Aβ42 production and amyloid deposition in vivo.
    Kanatsu K; Hori Y; Takatori S; Watanabe T; Iwatsubo T; Tomita T
    Hum Mol Genet; 2016 Sep; 25(18):3988-3997. PubMed ID: 27466196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
    Ling S; Zhou J; Rudd JA; Hu Z; Fang M
    Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling Alzheimer's. Scientists are close to figuring out how the disorder destroys brains. But will their knowledge save lives?
    Gorman C
    Time; 2000 Jul; 156(2):98-9. PubMed ID: 10977415
    [No Abstract]   [Full Text] [Related]  

  • 12. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?
    Ross JS; Imbimbo BP
    J Alzheimers Dis; 2010; 22(2):401-4. PubMed ID: 21149978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
    Shitaka Y; Mitani Y; Nagakura A; Miyake A; Matsuoka N
    Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):15-20. PubMed ID: 20628208
    [No Abstract]   [Full Text] [Related]  

  • 15. [Molecular pathology and therapeutics in Alzheimer's disease: amyloid beta-protein as a therapeutic target].
    Ohyagi Y
    Fukuoka Igaku Zasshi; 2006 Sep; 97(9):261-8. PubMed ID: 17134029
    [No Abstract]   [Full Text] [Related]  

  • 16. Alzheimer's disease sends the wrong signals--a perspective.
    Neve RL
    Amyloid; 2008 Mar; 15(1):1-4. PubMed ID: 18266116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how?
    Ziani-Cherif C; Mostefa-Kara B; Brixi-Gormat FZ
    Curr Pharm Des; 2006; 12(33):4313-35. PubMed ID: 17105430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease and other dementias: update on research.
    Schneider L
    Lancet Neurol; 2017 Jan; 16(1):4-5. PubMed ID: 27979354
    [No Abstract]   [Full Text] [Related]  

  • 19. Tarenflurbil: a shot on goal.
    Aisen PS
    Lancet Neurol; 2008 Jun; 7(6):468-9. PubMed ID: 18450518
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.